Oppenheimer assumed coverage of Alnylam (ALNY) with an Outperform rating and $500 price target The firm says Amvuttra’s uptake in ATTR-CM has been impressive, delivering about $300M sales in its second full quarter post-launch. Despite Amvuttra’s strong growth, Alnylam has been under pressure, mainly due to market concerns around potential deceleration of Amvuttra growth and elevating payer pushback. Although Oppenheimer anticipates Q4 2025 seasonality to impact Amvuttra sales, the firm thinks Amvuttra will continue to beat growth expectations in Q4 and beyond and anticipates upcoming sales/guidance announcements to drive 10%-20% upside in Alnylam.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target lowered to $491 from $525 at Bernstein
- Alnylam: Buy Rating Reaffirmed as Long-Term TTR Growth and Strategic Update Offset Near-Term Amvuttra Launch Concerns
- Alnylam to invest $250M to expand manufacturing facility in Massachusetts
- Seagate, Western Digital among additions to Nasdaq-100 on 12/22
- Ionis Pharmaceuticals price target raised to $100 from $85 at Leerink